In short-term (2 weeks) therapy, the dual ETAR/ETBR antagonist bosentan (1000 mg twice daily) has been shown to produce immediate and sustained haemodynamic benefit in patients with HF [31]. Here, EDNRB is linked to hydrops fetalis.